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It is a challenge to safely administer sustained release medicines to patients with dysphagia. Sustained
release tablets must not be crushed and multiparticulates with large particle sizes cause gritiness
reducing patient acceptability. The aim of this study was to develop “instant” jellies as delivery vehicles
incorporating sustained release microparticles for patients with dysphagia. Dry powder mixtures con-
taining gelling agents such as sodium alginate and calcium ions were hydrated in 20 mL of water and
formed a jelly texture within 10 min. The “instant” jellies demonstrated comparable properites to
commercial “read-to-eat” jellies in appearance, rheological/textural properties and in vitro swallowing
performance in an artificial throat model. Gliclazide sustained release microparticles were produced by
fluidized bed coating using Eudragit® NM 30 D and achieved 99% production yield and final coated
particle size (D50) of 198 ± 4.3 mm. Sustained gliclazide release was achieved over 15 h and the incor-
poration of the particles into the jellies significantly decreased the drug release rate. This novel drug
delivery system offers a patient-centric solution to the long-standing challenge of administering sus-
tained release medicines to patients with dysphagia and can potentially be used for paediatric patients.
© 2020 The Authors. Published by Elsevier Inc. on behalf of the American Pharmacists Association®. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
The older population (aged 65 years or over) is the fastest
growing subsection of the total population.1 Older adults are more
vulnerable to difficulties in swallowing (dysphagia) due to age-
related diseases and the natural process of aging.2 Dysphagia,
together with other factors such as multi-morbidity, polypharmacy
and cognitive impairments, brings significant challenge to medi-
cine administration to older patients.3 Solid oral dosage forms are
often modified to facilitate swallowing by crushing tablets or
opening capsules.4,5 However, this can be hazardous due to changes
in pharmacokinetics causing potential side effects or toxicity.6
Sustained release dosage forms can be beneficial for older pa-
tients in reducing dosing frequency and pill burden and thus
improving medicine adherence compared to immediate releasend Pharmaceutical Sciences,
ertfordshire, Hatfield, United
Inc. on behalf of the American Phaformulations.7,8 However, sustained release dosage forms are often
in the form of tablets that must not be crushed for administration
due to potential toxicity.6 Multiparticulate sustained release dosage
forms, such as coated pellets or mini-tablets filled in capsules and
to be sprinkled onto food, can be easier to swallow than tablets.9
However, these ‘sprinkles’ were poorly accepted by older patients
because of altered taste of food.10 The large particle size of the
multiparticulates (commonly in the range of 0.5e2.5 mm) can
cause grittiness and reduce patient acceptability.11,12 Small particles
(<250 mm) would reduce grittiness but can creat problems in
handling or require a delivery vehicle.
Jellies are considered to be highly palatable and acceptable to
patients and have been used as medicine dosage forms; for
example an oral immediate release jelly was marketed in Japan for
Donepezil for the treatment of Alzeimer's disease to help patients
with swallowing difficulties.13 Conventional food jellies were hard
and can stand freely on a plate; recently free-flowing granular
jellies were developed as swallowing aids for children and adults to
assist in tablet swallowing.14,15 Both hard and granular jellies have
demonstrated flow properties that can contribute to safermacists Association®. This is an open access article under the CC BY-NC-ND license
S. Patel et al. / Journal of Pharmaceutical Sciences xxx (2020) 1-112swallowing by patients with dysphagia, indicating their suitability
as medication aids for these patients.16 Recent formulation de-
velopments also included commercial technologies which convert
solid dosage forms such as tablets and pellets into semi-solid, gel-
like dosage forms by adding water to aid swallowing.17,18
Gliclazide is a sulfonylurea for the treatment of Type 2 diabetes.
Sustained release gliclazide (Diamicron SR) has been available for
some years as tablets which must not be crushed for administra-
tion. No liquid or multiparticulate sustained release gliclazide
formulation is currently available. Gliclazide is recommended to be
used with caution in geriatric patients associated to the side effects
of hypoglycaemia. Gliclazide 30 mg daily sustained release
formulation is considered to be approximately equivalent in ther-
apeutic effect to the standard immediate release formulation
(80 mg, given in 2e3 divided doses), thereby affording a lower dose
advantage, as well as the reduced frequency of dosing.19 Sustained
release gliclazide showed low incidence of hypoglycaemia even in
the elderly (0.14%).20 An “easy to swallow” non-solid sustained
release gliclazide formulation would benefit patients with
dysphagia who cannot swallow the sustained release tablet.
The aim of this study was to develop a powder composition that
can be hydrated before administratin to form an “instant” jelly and
to evaluate the feasibility of incorporating sustained release gli-
clazide microparticles into the jelly composition for administration
to patients with dysphagia.
Materials and Methods
Materials
Sodium alginate (Protanol GP 1740), low acyl gellan gum (Kel-
cogel F) and guar gum were donated by FMC Biopolymer (UK), CP
Kelco (UK) and B&V (Italy) respectively. Hydroxypropyl methyl-
cellulose (HPMC, Methocel E5) and polyethylene oxide (Sentry
Polyox WSR N10 LEO NF) was purchased from Colorcon, UK. Cal-
cium chloride and citric acid were purchased from Fischer Scientific
(UK), and dicalcium phosphate dihydrate was purchased from
Sigma Aldrich, UK. Hartley's ready to eat jelly (containing gelling
agents locust bean gum, xanthan gum and gellan gum) was man-
ufactured by Hain Daniels Group (UK) and purchased from ASDA
supermarket, UK. Ryukakusan jelly (agar based) was purchased
from Ryukakusan, Japan.
Gliclazide was purchased from Sinobio Chemistry Co Ltd, China.
Gliclazide sustained release 30 mg tablets (Diamicron) manufac-
tured by Servier were ordered from AAH pharmaceuticals, UK.
Microcrystalline cellulose microspheres (MCC, Cellets® 100) was
obtained from Pharmatrans-Sanaq AG, Switzerland. Eudragit® NM
30 D (Poly(ethyl acrylate-co-methyl methacrylate) and Silicon di-
oxide (Aerosil 200 Pharma) were purchased from Evonik AG, Ger-
many. Magnesium stearate was ordered from Acros Organics,
Belgium. Talc was purchased from Imerys Talc, Italy.
Development of “Instant” Jellies
The term “instant” jelly was used in this study to differentiate
from commercially available “ready-to-eat” jellies. It is a term
usually used to describe the preparation of food jellies from dry
powder mixtures involving heating and cooling. To ensure drug
stability, the “instant” jellies prepared in this study eliminated the
use of heating. Sodium alginate is known to form gels in the
presence of calcium ions at room temperature,21e23 which was
utilised to form the “instant” jelly structure. Two types of jellies
were developed mimicking the commercially available “ready-to-
eat” jellies, a free-standing jelly (using Hartley's ready to eat jelly as
reference comparator) and a granular, flowing jelly (similar toRyukakusan jelly, a swallowing aid for tablets). Free-standing jellies
were developed by mixing sodium alginate (0.5 and 1% w/v) or
sodium alginate mixed with another polymer (guar gum, poly-
ethylene oxide, HPMC or low acyl gellan gum, 50:50) and dicalcium
phosphate dihydrate (0.1e1% w/v) in 20 mL of deionised water
using a spatula until no dry powder could be seen. Citric acid
aqueous solution (1e10% w/v) was then added into the polymer
suspension and stirred for 30 s. The resultant mixturewas left to set
at room temperature for 5 min.
Granular jellies were developed by adding sodium alginate
(0.5e2% w/v) or sodium alginate mixed with another polymer
(guar gum or low acyl gellan gum, 50:50) in 10 mL of deionised
water and mixing using a spatula until no dry powder could be
seen. A low concentration calcium chloride aqueous solution
(0.1e0.3% w/v, 10 mL) was added to the polymer suspension and
continuously mixed for 30 s.
Evaluation of “Instant” Jellies
Visual Inspection of Jelly Formation
The jelly mixtures resultant from Section Development of
“Instant” Jellies were assessed using the following criteria:
 Appearance and texture: These were developed by visual in-
spection of the commercial jellies. For free-standing jelly (Har-
tley's jelly), the criteria included being easily cut with a spatula,
being firm enough that the angles produced by cutting retained
its shape and quivering or being wobbly when it was held on a
spatula.24 For granular jellies (Ryukakusan jelly), it contained
large gel-like granules throughout the mixture and flowed
when the container was inverted. Each developed jelly formu-
lation was given a “yes” or “no” answer indicating whether or
not the above criteria were met.
 Jelly formation time: This was the time for the primary structure
of the mixture to be stabilised (no change in appearance was
observed after this time). For free-standing jellies, this time was
the additional time needed after the 5 min setting time.
 Volume of residual water: Water that was not incorporated into
the structure of themixturewas poured out and the volumewas
measured.
Following the visual inspection one free-standing jelly compo-
sition (Jelly 1) and two granular jelly compositions (Jelly 2 and 3)
were selected and subjected to further evaluation.
Rheological and Textural Characterisation of the Jellies
ATA 1500 EX controlledestress rheometer (TA instruments) was
used to obtain oscillatory viscoelastic data. Measurements were
carried out at 25 C using parallel plate geometry (40mmdiameter)
for oscillatory stress sweep (torque 0.01e10,000 micro N.m at a
frequency of 10 rad/s) and frequency sweep (0.1e100 rad/s) tests.
Textural characteristics were evaluated using a texture analyser
(TA.XT. Plus, StableMicrosystems, United Kingdom). Two tests were
conducted: gel strength test for free-standing jellies and back
extrusion test for granular jellies. The gel strength wasmeasured by
depressing a standard 4 mm cylindrical (P/0.5) probe (Stable
Microsystems, United Kingdom) into a spherical jelly sample cut
into 4.5 cm diameter and 2 cm height. The back extrusion test was
conducted using an extrusion disc (35 mm) positioned centrally
over the container holding 100 mL of jelly sample and the disc
penetrated the sample to a depth of 20 mm at a 0.5 mm/s test
speed. The maximum force (g) used to reach this depth was the
measurement of firmness. The maximum negative force, when the
probe was drawn up at a speed of 0.5 mm/s, was the indication of
cohesiveness. Surface adhesion was determined by lowering the
Table 1
Processing Parameters for Drug Loading and Polymer Coating.
Processing conditions Drug layering Sustained release
coating
Nozzle size (mm) 0.5 0.5
Inlet air temperature (C) 70e80 30e32
Product temperature (C) 40e45 18e20
Atomization pressure (bar) 2.0 1.5
Fluidisation air velocity (m3/hr) 18 ± 0.5 18 ± 0.5
Spray rate (g/min) 1.5e2.0 1.1e2.0
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held on the surface of the sample for 30 s and pulled away at 2 mm/
s. The force (g) for withdrawal of the disc from the sample indicated
surface adhesion (adhesiveness). All measurements were carried
out at room temperature in triplicates.In Vitro Processing of the Jellies
An in vitro swallowing simulator e “Cambridge Throat” e was
used to evaluated the in vitro processing behaviour of the “instant”
jellies.25e28 Detailed descriptions of the use of the in vitromodel for
testing jellies were reported by Patel et al. 2019.16 In brief, the test
sample (5mL) was held within a 25mmwide dialysis tube attached
to the curved top of the model. Jelly 1 (free-standing jelly) was
manually fragmented into 4 mm pieces before putting into the
sample tube. By releasing a pin, a roller with an attached weight
(190 g) moved the bolus through the tubing. The roller movement
ended just before the area of the model representing the epiglottis.
An iPhone camera (6S, Apple, USA) was used to capture images of
the test sample flowing through the throat model at 30 frames per
second. The in vitro-oral transit time (OTT) and bolus length (BL) of
the test sample at area of the model representing the pharynx and
larynx juncture were calculated from the images.16 In vitro-OTTwas
calculated as the time taken by the roller to reach an angle of 120
as reported byMowlavi et al., 2016.27 ImageJ (Fiji) image processing
software was used to calculate BL by capturing the first image in
which the bolus front reached the pharynx and larynx juncture. BL
was measured as the length of the bolus from front to tail.16Evaluation of “Instant” Jellies as Delivery Vehicle for Sustained
Release Gliclazide Microparticles
Determination of Gliclazide Solubilities
The solubility profile of gliclazide was determined in liquid ve-
hicles at pH 1e13 at room temperature using serial dilutions of 0.1M
HCl (pH 1e7) and 1 M NaOH (pH 8e13) aqueous solutions. Excess
quantity of gliclazide was added into the liquid vehicle and shaken
for 72 h in a roller shaker (RollerMixer SRT9, Stuart Equipment, UK).
The pH value of the liquid was measured using a pH probe (WTW
inoLab, WTW GmbH, Germany) before and immediately after gli-
clazide addition and after 24 h. The pH was adjusted to the desired
level using 1 M HCl or 1 M NaOH solutions if necessary. Samples
(2 mL) were taken and centrifuged (MiniSpin Plus, Eppendorf AG,
Hamburg) at 14,500 rpm for 15min and 1mL or 0.1mL aliquot of the
supernatant was diluted using pH 7.4 (0.05 M) phosphate buffer.
Gliclazide concentration was determined using UV-Encapsulation efficiency; %¼ measured drug content in coated micro
theoretical drug content in coated microspectrophotometer (T80; PG Instruments Ltd., UK) at wavelength
226 nm. Measurements were made in triplicate.Preparation of Gliclazide Sustained Release Microparticles
Gliclazide was layered onto MCC cores (Cellets® 100, 100 g)
using a Wurster fluidized bed coater (Mini-Glatt, Glatt GmbH,
Germany). Gliclazide was milled for 2 h using a mini ball mill (160 g
batch size with 60  10 mm, 19  20 mm and 24  10 mm mini
balls at 450 rpm) (Copley Scientific, UK) and suspended (10% w/w)
in an aquous vehicle containing HPMC (1% w/w) and talc (1.9% w/
w). The drug layering process followed parameters shown in
Table 1 until 50% drug loading weight gain was reached.
The gliclazide layered Cellets (100 g) were coated using an
Eudragit® NM 30 D aqueous dispersion in a Wurster fluidized bed
coater (Mini-Glatt, Glatt GmbH, Germany). The polymer dispersion
was prepared by suspending talc in water using a magnetic stirrer,
followed by homogenisation at 10,000 rpm for 20 min (L4RT, Sil-
verson, UK). The talc suspensionwas added to the Eudragit®NM 30
D dispersion and stirred using a magnetic stirrer. The coating
process was conducted using parameters shown in Table 1 until 16,
20, 25 and 60% coating levels (CL)/weight gains were reached.
Magnesium stearate was added every 15 min (0.1 g for each addi-
tion) into the fluidized bed coater through an external feeding port
following the method reported by Mohylyuk et al. 2020.29 Silicon
dioxide was added into the coating chamber before the coated
microparticles were discharged to separate the free flowing parti-
cles from the particles stuck in the coating chamber. The collected
particles were cured in an oven at 40 C for 24 h. The percentage
yield was calculated based on the coated particles that were free
flowing without agglomeration.29 Particle size measurements of
the coated microparticles were made using a laser diffraction par-
ticle sizer (Sympatec HELOS/RODOS, Sympatec GmbH, Germany).
The average particle size was described as D50 (by volume). Surface
images of coatedmicroparticles were taken using scanning electron
microscopy (SEM) after the application of 25 nm gold coating
(Phenom ProX, Lambda Photometrics, UK).
Drug loading capacity of the microparticles was measured by
crushing 3.95 g coated microparticles (equivalent to 0.8 g theo-
retical gliclazide content). The powdered particles were added to
200mL of acetonitrile and shaken for 1 h, followed by filtration. Ten
millilitre of the filtrate was diluted to 200 mL using a mixture of
acetonitrile:water (2:3 v/v). The gliclazide concentration in the
resultant solution was analysed using high pressure liquid chro-
matography (HPLC, UK). A Synergi Fusion-RP column (size
250 4mm, Phenomenex, UK) was usedwith a flow rate of 0.9 mL/
min at ambient temperature. A 20 mL injection volume was used
with a detectionwavelength of 235 nm.Mobile phasewas prepared
using trimethylamine, trifluoroacetic acid, acetonitrile and water
(0.1:0.1:45:55 v/v). The drug loading capacity and encapsulation
efficiency were calculated as below:.
Loading capacity; %¼ drug content in coated microparticles; mg
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Jellies
Microparticles were incorporated into the jellies (Jelly 1, 2 and 3)
by mixing the required quantity (142 mg, equivalent to 30 mg
gliclazide) of the particles with the polymers (sodium alginate or
polymer mixture) and the jellies were subsequently prepared using
the methods described in Section Development of “Instant” Jellies.
In Vitro Dissolution Tests of Sustained Release Gliclazide
Microparticles With and Without Incorporation into Jellies
All dissolution tests were conducted in triplicate using USP II
apparatus with a paddle speed of 100 or 200 rpm (DIS 6000, Copley
Scientific, UK). The dissolution tests were performed in 900 mL of
pH 7.4 phosphate buffer (0.05M) for 14 h at 37 C. Gliclazide release
was determined using a UV-spectrophotometer (PG Instruments
Ltd., UK) at wavelength 226 nm. Samples tested included the
commercial gliclazide SR 30 mg tablet (Diamicron, Servier, UK), the
coated sustained release gliclazide microparticles (equivalent to
30 mg gliclazide) at varying coating levels (CL16, CL20, CL25, and
CL60) and coated gliclazide microparticles at CL20 and CL25
incorporated into the “instant” jellies (Jelly 1, 2 and 3). The disso-
lution of Jelly 1 incorporating the microparticles was tested in two
ways - as whole jelly and fragmented to 4 mm pieces. The
completion of drug release after each dissolution test was checked
by extending the dissolution run time for additional 6 h at 200 rpm
paddle speed and subsequently measuring the drug concentration
by UV at 226 nm.
Dissolution testing was also conducted using placebo jellies
(without the incorporation of the sustained release microparticles).
The pH change of the dissolution media during dissolution testing
of placebo jellies was measured using an ELIT PH2011 pH electrode
(NICO2000 Ltd, UK.) and recorded using a 6-channel pH monitor
(NICO2000 Ltd, UK).
Drug release in biorelevant media was conducted in pH 7.4
phosphate buffer containing FeSSIF powder (56 g FeSSIFF powder,
Biorelevant.com Ltd, UK, per 5 L of buffer solution). Samples from
dissolution vessels were withdrawn, without media replacement,
using an auto-sampler (Vankel 8000, LabX, Canada) and the drug
concentration was determined using HPLC as described in Section
Preparation of Gliclazide Sustained Release Microparticles.
Data Analysis
The similarity factor (f2) between different dissolution profiles
was calculated using Equation (3).30Table 2









0.5 0.5 1 _
0.5 0.5 2 _
0.5 0.5 5 _
0.5 0.5 10 _
0.5 0.1 2 _
0.5 0.2 2 _
0.5 0.4 2 _
0.5 1 1 _
1 0.5 1 _
0.5b 0.4b 2b Guar gumb
0.5 0.4 2 Polyethylene oxi
0.5 0.4 2 HPMC
0.5 0.4 2 Low-acyl gellan g
a Second gelling agent:sodium alginate (w:w) at 50:50.










where n corresponds to the number of time points and Rt corre-
sponds to drug release of the reference profile at time t, and Tt
corresponds to drug release of the test product at time t. The
closeness of the dissolution profile was indicated when f2 was be-
tween 50 and 100.
Prism Graphpad (version 7.0) was used to assess normality of
dissolution profiles using the Shapiro-Wilk test; normal distribu-
tion was rejected (p < 0.05). The Mann-Whitney U test was applied
to compare significant differences between dissolution profiles and
significance differences were accepted when p 0.05. The Shapiro-
Wilk test was used to assess normality of the texture analysis data
of jellies and normal distributionwas accepted. The unpaired T-test
was applied to compare significant differences between texture
profiles of jellies with and without microparticles.Results
Development and Evaluation of “Instant” Jellies
Visual Inspection of Jelly Formation
Table 2 shows the visual inspection results of free-standing jelly
formation using sodium alginate, dicalcium phosphate dihydrate
and citric acid. Generally, increasing the concentrations of the
polymer, the calcium salt or citric acid increased jelly formation
time. The composition of sodium alginate (0.5% w/v), dicalcium
phosphate dihydrate (0.4% w/v) and citric acid (2% w/v) met the
appearance and texture criteria in comparison to Hartley's ready-
to-eat jelly and showed relatively low volume of residue water
(6 mL); however the jelly formation time (11 min) was longer than
the requirement (less than 10 min) in the criteria. Mixing sodium
alginate in this composition with guar gum (50:50, w/w) reduced
jelly formation time to 6 min and the volume of residue water to
3 mL and this was selected as Jelly 1. Preliminary trials showed that
mixing sodium alginate solution with low concentration calcium
chloride solution resulted in jelly structure similar to the granular
Ryukakusan's jelly (data not shown). Table 3 shows visual inspec-
tion results of granular jelly formation at different sodium alginate
and calcium chloride concentrations. The composition of Jelly 2
(sodium alginate at 2% w/v and calcium chloride at 0.3% w/v)

















de ✓ 8 7
✓ 9 7
um ✓ 6 9
Table 3
Visual Inspection of Jelly Formation for Granular Jellies.





0.5 0.1 _ ✕ 3
1 0.1 _ ✕ 4
2 0.1 _ ✕ 7
0.5 0.2 _ ✕ 3
1 0.2 _ ✕ 7
2 0.2 _ ✕ 10
0.5 0.3 _ ✕ 2
1 0.3 _ ✕ 2
2b 0.3b _ ✓ 3
2 0.15 Guar gum ✕ 5
0.5c 0.15c Low-acyl gellan gumc ✓ 3
a Second gelling agent:sodium alginate (w:w) at 50:50.
b Composition of Jelly 2.
c Composition of Jelly 3.
S. Patel et al. / Journal of Pharmaceutical Sciences xxx (2020) 1-11 5comparison to the Ryukakusan's jelly and short jelly formation time
(3 min). Reducing the sodium alginate and calcium chloride con-
centration and mixing with low-acyl gellan gum obtained similar
jelly appearance, texture and jelly formation time (3 min) (Jelly 3).
There was no residual water in any of the granular jellies. Fig. 1
shows images of Jelly 1, 2 and 3, and the commercial reference
comparators.Rheological and Textural Characteristics of the Jellies
The representative oscillatory frequency sweeps are shown in
Fig. 2 for Hartley's jelly, Ryukakusan's jelly and Jellies 1, 2 and 3. All
of the jellies showed the same characteristic features: G0 domi-
nance over G” and a decline in complex viscosity h* over the fre-
quency range. A greater magnitude of G0 was observed for Jelly 1
and Jelly 2 compared to their respective commercial reference
products Hartley's jelly and Ryukakusan's jelly. Jelly 3 showed a
similar magnitude of G0 and G00 modulus compared to Ryukakusan's
jelly.
Similar gel strength was demonstrated by Jelly 1 (11.1 g ± 0.4 g)
in comparison to Hartley's jelly (13.36 g ± 1.47 g). The firmness,
cohesiveness and adhesiveness of granular jellies in comparision to
Ryukakusan's jelly are shown in Table 4. Jelly 2 showed much
higher firmness but lower cohesiveness than Ryukakusan's jellyFig. 1. Images of a) Hartley's jelly, b) Jelly 1, c) Ryukakusan jelly, d)and Jelly 3 demonstrated similar textural properties as the Ryu-
kakusan's jelly.
In Vitro Swallowing Process of the Jellies
Fig. 3 shows the images of the jellies in the in vitro swallowing
simulator at the time when the sample reached the pharynx and
larynx juncture. The in vitro-OTT and BL of the “instant” jellies were
comparable to those of the commercial jellies (Hartley's and Ryu-
kakusan jellies) reported previously.16
Evaluation of “Instant” Jellies as Delivery Vehicles for Sustained
Release Microparticles
Gliclazide Solubility
Gliclazide showed pH-dependent aqueous solubility with low
solubility at pH values below 6, slowly increasing solubility at pH
values 6e8 and rapid increasing above pH 8 (Fig. 4).
Preparation of Gliclazide Sustained-Release Microparticles
Successful drug layering and polymer coating processes were
achieved for the gliclazide microparticles. The yields for polymer
coatings at CL16, CL20, CL25 and CL 60 were 98.4, 99.3, 99.0 and
98.7% respectively. A representative SEM image of coated micro-
particles at CL25 is shown in Fig. 5. The D50 values of Cellets® 100Jelly 2 and e) Jelly 3 with and without coated microparticles.
Fig. 2. Frequency dependence of G0 and G” for a) Hartley's, b) Ryukakusan jelly c) Jelly 1, d) Jelly 2 and e) Jelly 3.
S. Patel et al. / Journal of Pharmaceutical Sciences xxx (2020) 1-116and the coated microparticles at CL16, CL20, CL25 and CL60 were
160 ± 2.1, 173 ± 3.6, 185 ± 2.4, 198 ± 4.3 and 208 ± 6.7 mm. The drug
loading capacity and encoproation efficiency of the microparticles
at CL25 were 20.2% and 95.8% respectively.Table 4
Textural Properties (Firmness, Cohesiveness and Adhesiveness) of Granular Jellies.
Product Firmness (g) Cohesiveness (g) Adhesiveness (g)
Ryukakusan's jelly 32.7 ± 0.2 14.9 ± 0.03 8.2 ± 0.3
Jelly 2 238.7 ± 22.9 5.3 ± 0.09 13.3 ± 1.29
Jelly 3 28.9 ± 1.4 14.2 ± 2.7 6.7 ± 0.1
Jelly 2 with
microparticles
206.1 ± 10.7 4.4 ± 0.8 11.4 ± 1.6
Jelly 3 with
microparticles
22.4 ± 4.3 10.3 ± 0.9 6.1 ± 0.4Incorporating Sustained Release Gliclazide Microparticles into the
Jellies
There was no change in colour or visual appearance of jellies
once the microparticles were added to the jellies (Fig. 1) and the
jelly formation times remained the same. No gliclazide was
detected in the residue water (3 mL) of Jelly 1. The gel strength of
Jelly 1 did not change significantly after incorporation of the mi-
croparticles (10.7 g ± 0.2 g). Similarly, no significant change was
noted for the texture properties of Jellies 2 and 3 after incorporation
of the microparticles (Table 3).In Vitro Dissolution Tests of Sustained Release Gliclazide
Microparticles With and Without Incorporation into Jellies
Fig. 6 shows gliclazide release profiles from coated microparti-
cles at coating levels CL16, CL20, CL25 and CL60 in comparison to
Fig. 3. Images of Jellies 1, 2 and 3 in the in vitro swallowing simulator at the juncture of the pharynx and larynx, with the oral transit time (OTT) and bolus length (BL).
S. Patel et al. / Journal of Pharmaceutical Sciences xxx (2020) 1-11 7Diamicron SR tablets in pH 7.4 phosphate buffer. Increasing the
coating level decreased drug release rate from the microparticles
and at CL25 the particles showed a f2 value of 54.2 (p ¼ 0.6653) in
comparison to Diamicron, demonstrating equivalent drug release
according to the Food and Drug Administration (FDA) guideline.28
Drug release was complete at the end of the dissolution test from
Diamicron and microparticles with coating levels of CL16, CL20 and
CL25, but not from microparticles with CL60.Fig. 4. Gliclazide pH-dependent solubility profile.



















Coated microparticles at CL16
Coated microparticles at CL20
Coated microparticles at CL25
Coated microparticles at CL60
Fig. 6. Gliclazide release from coated microparticles at coating levels CL16, CL20, CL25 and CL60 and the commercial Diamicron SR tablets in phosphate buffer pH 7.4 (n ¼ 3,
mean ± SD). CL: coating level.
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the “instant” jellies on drug release from the coated microparticles.
At coating level CL25, all three jellies reduced the drug release rate
with Jelly 1 showing the biggest reduction and significant differ-
ences were noted between microparticles alone and after incor-
poration into Jelly 1 (p  0.0018) and Jelly 2 (p ¼ 0.0425). No
significant difference was shown in drug release from microparti-
cles alone and microparticles incorporated into Jelly 3 (p¼ 0.0623).
Dissolution from microparticles in Jelly 1 as a whole jelly piece or
fragmented into small pieces resulted in equivalent drug release
profiles (f2 ¼ 84.2, p ¼ 0.2523). Drug release was not complete at
the end of the dissolution test from microparticles incorporated in
Jelly 1, 2 and 3 at CL25. When incorporating microparticles at CL20
into Jelly 1, drug release profile was equivalent to Diamicron SR
tablets (f2 ¼ 59.7, p¼ 0.930). Monitoring the pH changes during the
dissolution of placebo jellies showed that the pH of the dissolution
media decreased considerably for Jelly 1 from pH 7.4 to 7.0 whereas
no changes in pH were observed for jellies 2 and 3 (Fig. 8).
Increasing paddle speed from 100 to 200 rpm did not change the
drug release rate from microparticle alone. When the microparti-
cles were incorporated into all three jellies, drug release rates were
slightly higher at 200 rpm paddle speed than that at 100 rpm;
however, the differences were not significant (p > 0.05, Fig. 9). Drug
release from coated microparticles alone and in combination with
jellies were not significantly influenced by the use of biorelevant
dissolution media with all release profiles in FeSSIF comparable to
that in phosphate buffer and comparable to Diamicron SR tablets
(p > 0.05, Fig. 10). However, drug release from microparticles
incorporated in Jelly 3 was faster in biorelevant media than in
















Fig. 7. Gliclazide release from coated microparticles and in combination with JellieDiscussion
To ensure adherence and therapeutic outcomes of a pharma-
ceutical product it is critical to consider patient acceptability.31
Guidance issued by the European Medicines Agency (EMA) high-
lighted that acceptability must be an integral part of pharmaceu-
tical formulation development, especially for products that are
used in paediatric and geriatric populations.32,33 Commonly used as
food and desert and familiar to patients, gels and jellies are used as
medication delivery vechicles to improve patient acceptability.
Jellies are used in Japan as part of the dysphagia diet, as swallowing
aids for tablets and capsules and as marketed medication dosage
forms e.g. Donepezil jellies for the treatment of Alzeimer's dis-
ease.13,14,34,35 Kluk & Sznitowska (2014) applied oral gels as media
for administration of minitablets and pellets to paediatric
patients.12
Jellies that are manufactured in a hydrated form (ready-to-eat)
as pharmaceutical products contain a large proportion of water and
are thus likely to cause stability issues for certain drugs. They also
require antimicrobial preservatives. The concept of “instant” jellies
that are in solid (powder) forms and could be hydrated before
administration could mitigate these issues as medicine delivery
vechicles. The common method to prepare a gel/jelly is by heating
(typically to 70 C) and cooling, resulting in a conformation change
of the gelling agent from coil to helix forming a three-dimensional
structure.36 Heating causes instability of medicines and materials
that gel at room temperature would be ideal to prepare the
“instant” jellies without the need of increasing temperature. So-
dium alginate is known to form gels by calcium induced cross-
linking at room temperature.21e23 In this study, calcium chloride12 14
Diamicron 30mg SR tablet
No Jelly CL25
Jelly 1 (intact) incorporated with CL25
Jelly 1 (fragmented) incorporated with CL25
Jelly 1 (intact) incorporated with CL20
Jelly 2 incorporated with CL25
Jelly 3 incorporated with CL25
s 1, 2 and 3 in pH 7.4 phosphate buffer (n ¼ 3, mean ± SD). CL: coating level.









Fig. 8. The effect of placebo jelly dissolution on the pH level of pH 7.4 phosphate buffer.
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flowing granular jelly structure when they were mixed with so-
dium alginate solution. This was the result of the unique gelation
mechanism of sodium alginate when water soluble calcium salts
were used. Water soluble salts such as calcium chloride interacted
rapidly with sodium alginate, resulting in an inhomogeneous dis-
tribution of calcium ions. This led to the formation of a sharp gelling
zone at the polymer-calcium interface and a decreased gel forma-
tion towards the center of the gel.37 The granular structure of the
free-flowing jellies was caused by this inhomogeneous gelation. As
a result, it was problematic when calcium chloride solutions were
used to form the homogeneous, hard and free-standing jellies (data
not shown).
Dicalcium phosphate dihydrate is less soluble in cold water than
calcium chloride. When it was mixed with sodium aliginate as
powder and the mixture was hydrated by a citric acid solution,
calcium ions were slowly released by ion-exchange with citric
acid.37,38 This facilitated in situ gelation of sodium alginate forming
the homogeneous free-standing jelly texture. Calcium induced so-
dium alginate gels retained water through hydrogen bonds, and
during gel contraction, water was released from the gel structure
known as syneresis.38 Addition of guar gumwas able to reduce the
volume of residual water, through controlling water migration
during gel contraction because of guar gum's water binding
properties.39,40
Jellies 1 and 2 showed a greater magnitude of G0 and G” on the
frequency spectra of the rheology test, indicating a stronger gel-
network compared to their respective commercial reference
products. Jelly 2 also showed higher firmness in comparison to
Ryuakusan's jelly. Jelly 3 showed comparable rheological and
textural properties to Ryukakusan's jelly, likely because of its low
















Fig. 9. Gliclazide release from coated microparticles at 25% coating level alone and in combi
200 rpm paddle speeds. CL: coating level.structure by low acyl gellan gum. All three jellies demonstrated
in vitro swallowing behaviours in the artificial throat model similar
to previously reported that of the commercial jellies and thickened
fluids used in dysphagia patients.16 These behaviours included slow
in vitro oral transit and cohesive bolus movement, which were
believed to be important for safe-swallowing by dysphagia pa-
tients, indicating their potential safe use by these patients.16
As previously reported, the fluid bed coating process success-
fully produced sustained release microparticles of sizes <200 mm
with very low particle aggregation.29 The small particle size is
beneficial in improving patient acceptability. Oral grittiness (rough
mouthfeel) increased with increasing particle size and particles
below 263 mm showed low perception of grittiness when incor-
porated in HPMC gels.11 It is the intention of future studies to assess
acceptability of the delivery system in target patient groups.
In the current study, the jellies not only served as a deliver
vehicle for the coated particles, they also reduced the gliclazide
release rate from the dosage form. The jelly matrices provided an
additional barrier for drug release which possibly occurred through
a combination of drug diffusion through the jelly network and jelly
erosion.41 In phosphate buffer, ion-exchange occurred between
sodium in the dissolution media and calcium in the jelly matrix, a
process that loosened the structure of the gel network (un-cross-
linking) and over time facilitated the erosion of the jellies.41,42 Jelly
1 showed the strongest effect on drug release rate reduction in all
three jellies, likely because of its highest calcium content forming
strongest gel network structure and therefore slowest dissolution
of the jelly matrix. It was previously reported that an increase in
calcium concentration resulted in slower drug release from calcium
alginate beads due to an enhanced structural network, reduced
water intake and subsequently greater drug entrapment.41e43 In
addition, the dissolution of Jelly 1 decreased the pH level of the
dissolution media which in turn decreases gliclazide solubility
because of its pH-dependency. The reduction in drug release rate by
the jellies can be utilised to reduce the coating level required to
achieve the target drug release profile, as shown by the reduction of
coating level from 25% to 20% by Jelly 1 to obtain similar drug
release to Diamicorn SR tablets. It should be noted that these
findings were based on dissolution tests in large media volume;
further investigation is needed to understand the effect of jellies on
drug release in more realistic dissolution conditions.
Drug release from the microparticle-in-jelly system showed
relative robustness. Fragmentation of Jelly 1 to small pieces did not
show an effect on drug release, indicating that drug release will not
be influenced by chewing of the jelly. Furture study needs to
demonstrate whether chewing can affect the structural integrity of
the microparticles. Similarly, no significant effect was seen on drug12 14

















Coated microparticles at CL25
Jelly 1 (intact) incorporated with CL20
Jelly 3 incorporated with CL25
Diamicron 30mg SR tablet
Fig. 10. Gliclazide release from coated microparticles and in combination with Jellies 1 and 3 in pH 7.4 FeSSIF phosphate buffer (n ¼ 3, mean ± SD). CL: coating level.
S. Patel et al. / Journal of Pharmaceutical Sciences xxx (2020) 1-1110release when higher paddle speed was used during dissolution,
indicating low risk of changes in drug release due to variations in
gastrointestinal movements. Drug release was not significantly
affected by adding biorelevant (FeSSIF) powder in the dissolution
media. It needs to be noted that the FeSSIF buffer was used at pH 7.4
to be comparible to that of the phosphate buffer. The results
therefore only reflected the effect of the bile salts, lecithin and
surfactants content in the FeSSIF powder on drug release. It is ex-
pected that the pH of the intestinal content would be lower in
the fed state (pH 5.4e6.5) which could have an effect on drug
release.44
Solid dosage forms that can be converted into semi-solids before
administration offer both good stability and ease in swallowing and
are commercially attractive for paediatric patients and patients
with dysphagia. Recently a patented technology, the Parvulet™
Technology, was commercialised by Adare Pharmaceuticals, which
is in the format of a solid dosage form such as tablet and can be
converted into a gel-like semi-solid by addition of water to aid
patients' swallowing.17 Losan Pharma's Vismon® coating technol-
ogy applies pellet coating which swells and creates a viscous and
soft pellet pulp in themouth to be swallowed.18 The “instant” jellies
incorporating coated microparticles reported in this study showed
promises for sustained release drug delivery for patients who
cannot swallow tablets. The rheological, textural and in vitro
swallowing characteristics of the jellies demonstrated potential of
easy and safe swallowing for patients with dysphagia. The syner-
getic effect of the jellies in controlling drug release provides ben-
efits in reducing the coating level required to achieve desired drug
release profiles. The findings are also useful for the development of
sustained release dosage forms for paediatric patients.Conclusions
A novel drug delivery platform was developed using calcium
cross-linked alginate “instant” jellies as a vehicle for administration
of sustained release microparticles. Two types of jellies were suc-
cessfully produced that contained a dry powder mixture of sodium
alginate, other gelling agents and calcium salts and can be hydrated
rapidly before administration to form either a hard, free-standing
jelly or a granular, flowing jelly. Both types of jellies demon-
strated comparable properties to commercial “ready-to-eat” jellies
with regards to appearance, rheological and textural properties.
The “instant” jellies also showed ‘safe’ swallowing features with
in vitro oral transit time and cohesive bolus flow similar to previ-
ously reported values for commercial jellies and commonly used
thickened fluids for dysphagia patients. Sustained release gliclazide
microparticles were successfully manufactured using fluidised bedcoating, with final particle size D50 < 200 mm, 99% production yield
and adjustable drug release profiles that can be attuned to be
comparable to the marketed gliclazide sustain release tablet.
Incorporating themicroparticles into the jellies did not significantly
change the jelly appearance or structure. The jellies further reduced
drug release rate from the coated particles depending on the jelly
composition, offering a possibility of developing sustained release
formulations incorporating microparticles in jellies with attunable
drug release. The novel drug delivery system offers a promising
solution for the long-standing challenge of administering sustained
release medicines to paediatric patients and patients with
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